Avita is seen as a growth company, therefore the market expects to see growth in procedure numbers.
The market got scared when the procedures volumes slightly decreased last quarter and therefore were thinking recell was somehow not a good product and not gaining widespread adaptation.
This announcement should reassure everyone, and it is just a matter of time before recell becomes the new standard of care in all of its indications.
- Forums
- ASX - By Stock
- AVH
- AVH on NASDAQ
AVH on NASDAQ, page-700
-
- There are more pages in this discussion • 244 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.74 |
Change
0.110(4.18%) |
Mkt cap ! $186.5M |
Open | High | Low | Value | Volume |
$2.74 | $2.77 | $2.66 | $865.1K | 317.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 1164 | $2.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.75 | 400 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 736 | 2.730 |
4 | 7457 | 2.720 |
4 | 6530 | 2.710 |
3 | 36189 | 2.700 |
2 | 24375 | 2.690 |
Price($) | Vol. | No. |
---|---|---|
2.750 | 2241 | 2 |
2.760 | 10348 | 6 |
2.770 | 16094 | 4 |
2.780 | 7886 | 4 |
2.790 | 3212 | 2 |
Last trade - 13.53pm 15/07/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online